{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:34:37Z","timestamp":1771054477038,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2002,10,3]],"date-time":"2002-10-03T00:00:00Z","timestamp":1033603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The objective of this study was to determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5\u2010FU) and daily oral thalidomide in patients with metastatic renal cell carcinoma (RCC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Between June, 2000 and January, 2001, 21 patients with metastatic RCC were enrolled onto this multi\u2010institutional Phase II study of gemcitabine at 600 mg\/m<jats:sup>2<\/jats:sup> per day on Days 1, 8, and 15; 5\u2010FU at 150 mg\/m<jats:sup>2<\/jats:sup> per day by continuous IV infusion through a permanent catheter on Days 1\u201321; and oral thalidomide on Days 1\u201328 starting at a dose of 200 mg daily. After the first 2 weeks of therapy, the thalidomide dose was escalated by 100 mg per day every week to a maximum dose of 400 mg per day unless it was precluded by toxicity. Treatment cycles were repeated every 28 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A high rate of venous thromboembolism (VTE) was observed. Five patients developed deep vein thrombosis (DVT), three patients developed pulmonary embolization (PE), and one patient suffered a fatal cardiac arrest preceded by hemoptysis, for an overall VTE rate of 43%. Of the 18 assessable patients, there were no complete responses and 2 partial responses (objective response rate, 10%; 95% confidence interval, 1\u201330%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The addition of thalidomide to gemcitabine and 5\u2010FU did not improve the objective response rate previously observed with gemcitabine and 5\u2010FU alone and added significant vascular toxicity. The authors recommend against further development or use of this three\u2010drug regimen. Cancer 2002;95:1629\u201336. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10847<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10847","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T01:58:50Z","timestamp":1034128730000},"page":"1629-1636","source":"Crossref","is-referenced-by-count":96,"title":["A high rate of venous thromboembolism in a multi\u2010institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma"],"prefix":"10.1002","volume":"95","author":[{"given":"Apurva A.","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.51.1.15"},{"key":"e_1_2_6_3_2","first-page":"1010","volume-title":"Comprehensive textbook of genitourinary oncology","author":"Chow W","year":"2000"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2530"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01041-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67889-5"},{"key":"e_1_2_6_7_2","first-page":"42","article-title":"Chemotherapy for advanced renal\u2010cell carcinoma: 1983\u20131993","volume":"22","author":"Yagoda A","year":"1995","journal-title":"Semin Oncol."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940801)74:3<916::AID-CNCR2820740319>3.0.CO;2-Z"},{"key":"e_1_2_6_9_2","first-page":"301","volume-title":"The chemotherapy sourcebook","author":"Schilsky R","year":"1992"},{"key":"e_1_2_6_10_2","first-page":"6110","article-title":"Action of 2\u2032,2\u2032\u2010difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang P","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_6_11_2","first-page":"2811","article-title":"Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5\u2010fluoro\u20102\u2032\u2010deoxyuridine in HT\u201029 colon cancer cells","volume":"4","author":"Ren Q","year":"1998","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2419"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1004"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_6_15_2","first-page":"728","article-title":"Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies","volume":"59","author":"Bellamy WT","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_6_16_2","first-page":"6702","article-title":"Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease","volume":"52","author":"Teicher BA","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-423"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90008-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057793"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.509"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00178196"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10623329909053411"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.12.927"},{"key":"e_1_2_6_26_2","first-page":"535","article-title":"Markers of vascular damage in lupus pregnancy","volume":"15","author":"Direskeneli H","year":"1997","journal-title":"Clin Exp Rheumatol."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90122-X"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10528"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf008"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010915)92:6<1567::AID-CNCR1483>3.0.CO;2-L"},{"key":"e_1_2_6_32_2","first-page":"180a","article-title":"Phase II trial of thalidomide in renal cell carcinoma","volume":"20","author":"Escudier B","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_33_2","first-page":"180a","article-title":"Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin\u20102 (IL\u20102) based therapy","volume":"20","author":"Li Z","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_34_2","first-page":"365a","article-title":"Phase II trial of thalidomide in patients with metastatic renal cell carcinoma (RCC)","volume":"20","author":"Vuky J","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_35_2","first-page":"265a","article-title":"Phase II study of thalidomide(T) in advanced refractory metastatic renal cell cancer (MRCC): a single institution experience","volume":"20","author":"Novik Y","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_36_2","first-page":"265a","article-title":"A Phase II study investigating the use of thalidomide in conjunction with interferon in patients with metastatic renal cell carcinoma","volume":"20","author":"Nathan P","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_37_2","article-title":"Thalidomide associated deep vein thrombosis and pulmonary emboli","author":"Benett CL","journal-title":"Am J Med"},{"key":"e_1_2_6_38_2","first-page":"55a","article-title":"Phase II trial of thalidomide and BCNU in recurrent high\u2010grade gliomas","volume":"20","author":"Fine H","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442516"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1614"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901201)66:11<2387::AID-CNCR2820661123>3.0.CO;2-U"},{"key":"e_1_2_6_42_2","first-page":"112","article-title":"Activated\u2010protein\u2010C resistance in cancer patients","volume":"27","author":"Green D","year":"1997","journal-title":"Haemostasis."},{"key":"e_1_2_6_43_2","first-page":"9N","article-title":"Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic\u2010uremic syndrome","volume":"87","author":"Moake JL","year":"1989","journal-title":"Am J Med."},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-7-199804010-00004"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10847","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:57:01Z","timestamp":1760277421000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,3]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,10,15]]}},"alternative-id":["10.1002\/cncr.10847"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10847","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,3]]}}}